Dr. Frederick Sancilio reports

LOBE SCIENCES APPOINTS TRACY L. GOEKEN, M.D., AS CHIEF MEDICAL OFFICER

Lobe Sciences Ltd. has appointed Tracy L. Goeken, MD, as chief medical officer, effective Oct. 20, 2026. Dr. Goeken most recently served as chief medical officer at Linical, a global clinical research organization, where he led clinical development strategy and medical oversight of clinical trials across multiple therapeutic areas.

"We are delighted to welcome Dr. Goeken to Lobe as we prepare for the next stage of clinical development," said Dr. Frederick D. Sancilio, chairman and chief executive officer of Lobe Sciences. "His clinical development and regulatory experience, including a phase 3 generalized anxiety disorder study, bring directly relevant expertise to our team. We are preparing a U.S. investigational new drug (IND) application for L-130, our psilocin-based candidate for generalized anxiety disorder and advancing S-100, our oral lipid formulation for sickle cell disease, toward phase 3 development. Dr. Goeken will play a central role in designing and executing the studies needed to move both programs forward."

Dr. Goeken brings more than 20 years of experience in clinical development, regulatory strategy and medical affairs, including senior roles at Linical, Somahlution, Nuron Biotech and Pharm-Olam International. He has contributed to regulatory approvals for multiple products across FDA (Food and Drug Administration) and EMA (European Medicines Agency) jurisdictions, as well as successful FDA orphan drug and fast-track designation efforts. He also secured EMA acceptance of MRI biomarkers as a primary end point in a pivotal multiple sclerosis trial and built and led global medical affairs and pharmacovigilance organizations. His clinical development experience includes a phase 3 generalized anxiety disorder study, phase 1 sickle cell disease studies, and phase 2 and phase 3 migraine and pain studies, just to name a few. Dr. Goeken earned his medical degree from St. Christopher's College of Medicine, with clinical training through Louisiana State University Health Sciences Center.

"Lobe's proprietary drug candidates and the research supporting them are what attracted me to the company," said Dr. Goeken. "L-130 offers a compelling opportunity to explore the therapeutic potential of psilocin at doses below those that cause hallucinations, while S-100 builds on prior clinical research in sickle cell disease. I look forward to working with the team to advance these programs toward meaningful new treatment options."

Market-making engagement

The company also announces that it has engaged Independent Trading Group (ITG) Inc. to provide market-making services for its common shares, commencing Oct. 19, 2026. ITG will provide liquidity with the objective of supporting a fair and orderly market, in accordance with applicable securities laws and Canadian Securities Exchange (CSE) policies. The services are not intended to influence the market price of the company's shares.

Under the agreement, ITG will receive $6,000 per month, plus applicable taxes. The agreement has an initial term of one month and will automatically renew for successive one-month terms unless terminated by either party on 30-day notice. The agreement contains no performance-based compensation, and fees are not contingent on the company's share price or trading volume. No shares or options will be issued as compensation. ITG and the company are unrelated and unaffiliated entities. At the time of the agreement, neither ITG nor its principals held a direct or indirect interest in the company's securities.

ITG's address is 33 Yonge St., suite 420, Toronto, Ont., M5E 1G4. ITG may be contacted at info@itg84.com or 438-259-2141 extension 2141.

About Lobe Sciences Ltd.

Lobe Sciences is a clinical-stage biopharmaceutical company developing therapies for neurological conditions and rare diseases. Its lead neurological candidate, L-130 (Conjugated Psilocin), is a patented new chemical entity being developed initially for generalized anxiety disorder. L-130 is designed to deliver psilocin directly. Its development program is evaluating whether controlled doses below hallucinogenic levels can provide therapeutic benefit. The company is also developing S-100, an oral lipid formulation for sickle cell disease.

We seek Safe Harbor.